2018•Annals of OncologyOpen access
Which of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?
Motohiro Tamiya, Akihiro Tamiya, Hidemichi Suzuki, Kenji Nakahama, Yoshihiko Taniguchi, Kei Kunimasa, Michio Kimura, Tomio Inoue, Kazumi Nishino, T. Hirashima, Shinji Atagi, Fumio Imamura, Toru Kumagai
Open full text 8 citations
Abstract
Background: In epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), there are various treatment challenges. Most patients develop resistance and relaps within 1-1.5 years after first-line EGFR- tyrosine kinase inhibitor (TKI) treatment [1st- and 2nd- generation (G) TKIs]. Some studies suggest that afatinib may overcome the tumor heterogeneity.